Journal article
Pretreatment with dual antiplatelet therapy in patients with ST-elevation myocardial infarction
MB Yudi, O Farouque, N Andrianopoulos, AE Ajani, A Brennan, J Lefkovits, CM Reid, W Chan, SJ Duffy, DJ Clark
Catheterization and Cardiovascular Interventions | WILEY | Published : 2018
DOI: 10.1002/ccd.27325
Abstract
Background: The optimal time to administer P2Y12 inhibitors in patients with ST-elevation myocardial infarction (STEMI) remains to be defined. We sought to assess whether a pretreatment strategy was associated with improved coronary reperfusion and clinical outcomes. Methods: Consecutive patients from the Melbourne Interventional Group registry (2005–2014) who presented with STEMI and underwent primary PCI were included. Those who received any P2Y12 inhibitor prior to arrival in the cardiac catheterisation laboratory were included in the pretreatment group. The primary endpoints were the proportion of patients with initial TIMI flow grade <3 and in-hospital bleeding. The secondary endpoints ..
View full abstractGrants
Awarded by Pfizer
Funding Acknowledgements
[ "The Melbourne Interventional Group acknowledges unrestricted educational grant funding from: Abbott Vascular, Astra-Zeneca, Medtronic, MSD, Pfizer, Servier, and The Medicines Company. These companies do not have access to the data, and do not have the right to review manuscripts before publication.", "Dr. Yudi is supported by a combined National Health and Medical Research Council Postgraduate Scholarship (APP 1115163) and a National Heart Foundation Health Professional Scholarship (Award ID 101130). Dr. Duffy's & Professor Reid's work is funded by National Health and Medical Research Council of Australia Grants." ]